# 3BNC117 and 10-1074 in HIV-infected Individuals

> **NCT02825797** · PHASE1 · COMPLETED · sponsor: **Rockefeller University** · enrollment: 34 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **DRUG:** 3BNC117
- **DRUG:** 10-1074
- **OTHER:** Analytical treatment interruption
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02825797
- **Lead sponsor:** Rockefeller University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-08-15
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02825797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02825797, "3BNC117 and 10-1074 in HIV-infected Individuals". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02825797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*